AFT and Natera launch phase III breast cancer MRD-guided therapy trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to AFT and Natera launch phase III breast cancer MRD-guided therapy trial

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Gu

October 5, 2026 8:00 AM EDT

Trial will use Nateras ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentechs investigational oral SERD, aiming to spare patients unnecessary CDK4/6 inhibitor exposure and associated toxicities

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)-- Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment... More